Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease
Sponsor: Fred Hutchinson Cancer Center
Listed as NCT05996627, this PHASE2 trial focuses on Chronic Graft Versus Host Disease and remains actively recruiting participants. Sponsored by Fred Hutchinson Cancer Center, it has been updated 13 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Jun 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fred Hutchinson Cancer Center
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .